12:00 AM
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CYT003-QbG10: Additional Phase II data

Cytos reported additional data from a 12-week, double-blind, German Phase II trial in 63 allergic asthma patients requiring long-term treatment with inhaled corticosteroids (ICS). Seven injections of 900 µg CYT003-QbG10 significantly increased the proportion of patients whose asthma was well controlled as measured by an...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >